

Dr Debashis Sarker's publications

- Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, De Bono JS, Swanton C. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. *Br J Cancer* 2010;103(5):607-12
- Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I et al., Quinone oxidoreductase-2 mediated prodrug cancer therapy. *Sci Transl Med* 2010; 2, 40ra50
- Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. *Br J Cancer* 2010; 102(7):1106-12
- Banerji U, Camidge DR, Verheul HMW, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-Sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a Phase I open-label multicentre trial in patients with advanced cancer. *Clin Cancer Res* 2010;16(5):1613-23
- Carden C, Sarker D, Yap T, Postel-Vinay S, Attard G, Banerji U, Garrett M, Thomas G, Workman P, Kaye S, de Bono JS. Can Molecular Biomarker-Based Patient Selection In Phase I Trials Accelerate Anticancer Drug Development? *Drug Discov Today* 2010;15(3-4):88-97
- Sarker D, Reid A, Yap T, de Bono JS. Targeting the PI3Kinase pathway in prostate cancer. *Clin Cancer Res* 2009;15(15):4799-805
- Sarker D, Molife R, Evans TRJ, Judson I, et al. A phase 1, pharmacokinetic and pharmacodynamic study of TKI258, a novel oral multitargeted receptor tyrosine kinase inhibitor in patients with solid tumors. *Clin Cancer Res* 2008; 14(7):2075-81
- Sarker D, Pacey S, Workman P. Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. *Biomarkers Med.*2007;1(3):399-417
- Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. *Adv Cancer Res* 2007; 96: 213-268

- Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. *Br J Cancer*. 2006 Oct 9;95(7):767-74
- Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarker D, Jenner A, de Bono JS, Steward W. A phase I study of intravenous TAZ-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. *Ann Oncol*. 2006; 17(8):1313-1319
- Liu W, Baird R, Sarker D, Powles T. Antiapoptotic Effect of Growth in Leukaemia. Letter to editor: re. Negative effects of G-CSF treatment after allogeneic BMT for acute leukaemia by Ringden et al. (*J Clin Oncol*. 22: 416-423). *J Clin Oncol* 2005 23: 649
- Thirlwell C, Sarker D, Stebbing J & Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. *Clinical Lymphoma* 2003, 4: 86-92.
- Sarker D, Thirlwell C, Nelson M, Gazzard B, Bower M. Leptomeningeal disease in AIDS related non- Hodgkin's Lymphoma. *AIDS* 2003 11;17(6):861-5
- Esdale B, Davis M, Portsmouth S, Sarker D, et al. The immunological effects of concomitant HAART and liposomal anthracycline treatment of HIV-1 associated Kaposi's Sarcoma. *AIDS* 2002;16:2344-7
- Sarker D, Bower M. Alitretinoin Gel for Kaposi's Sarcoma. *Retinoids Lipid-Soluble Vit Clin Pract*, 2002; 18:40-42

Textbook Chapters

- Yap TA, Sarker D, Kaye SB, de Bono JS. Functional imaging: clinical applications in molecular targeted therapy. Husband and Reznak's Imaging In Oncology, 3rd Ed. Chapter 62, eds. JE Husband & RH Reznak, CRC Press 2009
- Pacey S, Sarker D, Workman P. Pharmacokinetics and Pharmacodynamics in Drug Development. *The Encyclopedia of Cancer*, 2nd Ed. vol 3 pp 2306-2309, ed. M. Scwab, Springer 2008
- Molife R, Karavasilis V, Sarker D, Reid A, Attard G, Parker C and de Bono JS. What are the best targets for investigational therapy? *ASCO Prostate Cancer Symposium Educational Book* 2007